Crowe Laboratory
-
Vanderbilt awarded R&D 100 Gold Medal for discovery of monoclonal antibodies that protect world against COVID-19
Dr. James Crowe, Robert Carnahan and their colleagues in the Vanderbilt Vaccine Center won the Gold medal in the 2022 R&D 100 awards for their discovery and development of long-acting antibodies that protect against COVID-19. The discovery of these antibodies has led to the development of Evusheld, pre-exposure therapy to prevent COVID-19 for adults and children over 12 with compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine. Read MoreAug 24, 2022
-
Vanderbilt researchers take leadership role in COVID-19 vaccine development
Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes. Read MoreDec 18, 2020
-
VUMC joins international effort to speed vaccine development
VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections. Read MoreJun 6, 2019
-
Research lab honored by World Vaccine Congress
The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week. Read MoreApr 12, 2018